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Eighty-one patients treated with high-dose therapy and autologous stem cell transplantation (ASCT) as part
of salvage therapy after a frontline ASCT were included in a retrospective analysis. The median time between
the ﬁrst and the salvage ASCT was 47 months. After salvage ASCT, 75 patients (93%) achieved at least a partial
response, including 67% very good partial responses, and no toxic death was reported. Sixteen patients (20%)
underwent consolidation therapy, whereas 30 patients (37%) underwent some form of maintenance therapy
after salvage ASCT. For all patients, the median overall survival (OS) was 10 years from diagnosis and 4 years
from salvage ASCT. The median progression-free survival (PFS) from the date of the ﬁrst ASCT to the date of
the ﬁrst relapse was 40 months, and the median PFS from the date of salvage ASCT to the date of subsequent
progression was 18 months. In the multivariate analysis of prognostic factors, three independent factors
unfavorably affected PFS: a short duration of response to the ﬁrst ASCT (cut-off value of 24 months),
a response less than a very good partial response after salvage therapy, and no maintenance treatment after
salvage ASCT. Age over 60 years and a short duration of response after the ﬁrst ASCT were the two factors
adversely affecting OS from the time of diagnosis and OS from the time of salvage ASCT. Our data show that
salvage ASCT is a feasible option that should be routinely considered at the time of relapse for patients with
a response duration of more than 2 years to frontline high-dose therapy.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION dexamethasone achieved superior results compared with
Autologous stem cell transplantation (ASCT) after high-
dose melphalan is the treatment of choice for patients with
symptomatic multiple myeloma (MM) who are younger than
65 years of age [1,2]. The incorporation of novel agents into
this strategy has markedly improved progression-free
survival (PFS) and overall survival (OS) of this group of
patients over the last decade [3]. Nevertheless, almost all
patients ultimately relapse, and no plateau is observed in the
survival curves. At the time of disease recurrence, no one
standard salvage approach is available; instead, various
therapeutic options are used, including novel agentebased
therapy, administered for a ﬁxed duration of time or until
progression.
In a pivotal trial for the approval of bortezomib as mon-
otherapy in patients with relapsed and refractory MM, the
median PFS was 7 months [4], whereas in pivotal trials for
the approval of lenalidomide in combination with dexa-
methasone in the same group of patients, the median time to
progression was approximately 11 months [5,6]. A recent
prospective, randomized, phase III study showed that
a triplet combination of bortezomib, thalidomide, andedgments on page 449.
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12.11.013thalidomideedexamethasone alone in patients relapsing
after ASCT, with a median time to progression of 19.5 versus
13.8 months, respectively [7]. This study suggested that
combinations consisting of both an immunomodulatory drug
and a proteasome inhibitor are a valuable option at the time
of relapse. However, when a frozen graft is available, it is also
possible to repeat high-dose therapy in patients who previ-
ously responded to the frontline application of high-dose
melphalan and ASCT [8]. Over time, many reports have
demonstrated the feasibility of this salvage strategy [9-19].
Most data are available from retrospective studies and are
based on single-center experiences with small numbers of
selected patients. In this setting, PFS has been shown to
range from 7 to 22 months, and treatment-related mortality
was acceptable, ranging from 0% to 8%. Various prognostic
factors for prolonged PFS have been described, such as
the duration of response to the ﬁrst high-dose therapy
[9,10,13-16,19] or the number of lines of therapy before
salvage ASCT [9,10]. Here, we report the results of a retro-
spective analysis of salvage ASCT conducted in three French
centers. Our goals were to identify prognostic factors for
prolonged PFS and OS.METHODS
Patients
In this retrospective analysis, all consecutive patients treated between
1995 and 2009 at centers of Nancy, Dijon, and Nantes with high-dose
therapy and ASCT as part of salvage therapy after a frontline single or
tandem ASCT and a subsequent relapse were included. To have a reliableTransplantation.
Table 1
Patient Characteristics at Diagnosis and First High-Dose Therapy Step
Variable Patients (N ¼ 81)
Median age at diagnosis (range) 55 (30-67)
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were not included in the present analysis. The choice of salvage ASCT instead
of other options was left to the treating physician and was also dependent
on stem cell availability. In addition, patients had to present with adequate
cardiac, lung, liver, or renal function, according to each center’s policy.Male 47 (58%)
Female 34 (42%)
Durie-Salmon stage
I 4 (5%)
II 9 (11%)
III 68 (84%)
International Staging System
1 40 (49%)
2 22 (27%)
3 14 (17%)
Missing data 5 (7%)
Isotype
IgG 53 (65%)
IgA 10 (12%)
Light chain 18 (23%)
Induction regimen before ﬁrst ASCT
VAD 69 (85%)
VMCP-VBAP 4 (5%)
Bortezomib-dexamethasone 8 (10%)Response Criteria
Response and progression were deﬁned according to the International
Myeloma Working Group criteria [20]. Brieﬂy, a complete response was
deﬁned as negative immunoﬁxation of serum and urine, disappearance of
soft tissue plasmacytoma, and 5% plasma cells in the bone marrow. Very
good partial response (VGPR) was deﬁned as serum and urine M-protein
detectable only by immunoﬁxation or as a 90% or greater reduction in serum
M-protein plus a urine M-protein level of <100 mg per 24 hours. Partial
response (PR) was deﬁned as a reduction in serum M-protein of at least 50%
and by a reduction of at least 90% or an absolute value of <200 mg per 24
hours in urine M-protein. Stable disease was deﬁned as not meeting any
response criteria, and progressive disease was deﬁned as a conﬁrmed
increase of 25% of M-protein from baseline. Relapse was deﬁned as the
reappearance of serum or urine M-protein or the development of new bone
lesions, plasmacytoma, or hypercalcemia. Response post-ASCT was assessed
at a maximum 100 days post transplantation, and patients were followed
approximately every 3 months thereafter.Conditioning regimen before ﬁrst ASCT
Melphalan 200 mg/m2 40 (49%)
Melphalan 140 mg/m2 23 (28%)
Melphalan 140 þ 8 Gy total body irradiation 12 (15%)
Other 6 (7%)
Tandem ASCT 29 (36%)
Response after ﬁrst high-dose therapy
VGPR 58 (72%)
PR 19 (23%)
SD 4 (5%)
Maintenance therapy after ﬁrst high-dose therapy
Interferon-a 24 (30%)
Thalidomide 13 (16%)
Lenalidomide 6 (7%)Statistical Analysis
PFS1 was deﬁned from the date of the ﬁrst ASCT to the date of ﬁrst
relapse or progression. PFS2 was deﬁned from the date of salvage ASCT to
the date of subsequent relapse or progression. OS rates were estimated from
the date of diagnosis or from the date of relapse to the date of death or to the
date of the last follow-up for patients who were still alive. Kaplan-Meier
curves for PFS and OS were plotted and compared using a log-rank test.
Predictive factors were determined by univariate analysis using Kaplan-
Meier curves and the log-rank test. Only predictive factors with a signiﬁ-
cant result (P < .05) in univariate analysis entered multivariate analysis,
using Cox regression. Statistical analysis was performed using SAS 9.3 (SAS
Institute, Cary, NC).Other 4 (5%)
None 34 (42%)
VAD indicates vincristine, adriamycin, dexamethasone; VMCP-VBAP,
vincristine, melphalan, cyclophosphamide, prednisone-vincristine, carmus-
tine, doxorubicin, prednisone; SD, stable disease.RESULTS
Patients
From January 1995 to December 2009, 81 patients were
treated with salvage ASCT. Patient characteristics at the time
of diagnosis of symptomatic MM are shown in Table 1. The
median time from diagnosis to the ﬁrst ASCT was 4 months.
Thirty-six percent of patients received tandem ASCT, 95%
responded to high-dose therapy, and 58% received some
form of maintenance therapy, the median duration of which
was 16 months (range, 1 to 64).
Patient characteristics at the time of salvage ASCT are
listed in Table 2. The median time between the ﬁrst and the
salvage ASCT was 47 months (range, 13 to 168). Ninety-ﬁve
percent of patients received induction therapy before
salvage ASCT, which consisted of novel agentebased regimen
in half, and four patients proceeded to ASCT without any
salvage chemotherapy. Only 26 patients (32%) received
more than 2 lines of therapy before salvage ASCT. At the
time of salvage ASCT, 67 patients (83%) had achieved at
least a PR to induction therapy, 10 (12%) had not responded
to induction, and 4 were in an untreated relapse.
Fifty-eight of 81 patients (72%) received stem cells that had
been harvested before the ﬁrst ASCT. For 23 patients (28%),
stem cells were harvested after the ﬁrst relapse using
granulocyte colony-stimulating factor alone (13 patients),
cyclophosphamide þ granulocyte colony-stimulating factor
(6 patients), or plerixafor þ granulocyte colony-stimulating
factor (4 patients). After salvage ASCT, 75 patients (93%)
achieved at least a PR, including 67% VGPR, and no toxic
death was reported. Sixteen patients (20%) received consol-
idation therapy, whereas 30 (37%) received some form of
maintenance therapy after salvage ASCT.Survival and Prognostic Factors
The median follow-up time for living patients was 7 years
(range, 2.1 to 16.6). The median OS was 10 years from diag-
nosis and 4 years from salvage ASCT (Figure 1). The median
PFS1 was 40 months (range, 10 to 152), and the median PFS2
was 18 months (range, 2 to 64) (Figure 1).
The duration of the second response was found to be
related to PFS1: The median PFS2 was 26.4 months in
patients experiencing their ﬁrst relapse more than 40
months after the ﬁrst ASCT versus 14 months in patients
relapsing within the ﬁrst 40 months after their ﬁrst ASCT,
P ¼ .001 (Figure 2). A cut-off value of 24 months for relapse
after the ﬁrst ASCTwas also found to signiﬁcantly affect PFS2,
with a duration of second response of 9 versus 18 months
(P ¼ .0096) for patients relapsing within 24 months versus
those with a relapse more than 24 months after the ﬁrst
ASCT. The analysis was not performed for a shorter duration
of ﬁrst response due to the small number of patients
relapsing within 18 months after their ﬁrst ASCT. In addition,
the duration of response after the ﬁrst ASCT also affected OS.
The median OS rate from salvage therapy was longer in
patients relapsing 24 or 40 months after their ﬁrst ASCT
versus others (median 7.2 and 7.3 versus 2.4 and 3.4 years,
respectively; P < .05).
The duration of response after salvage ASCT was also
signiﬁcantly affected by the use of maintenance therapy
(Figure 3). Results of the univariate analysis of prognostic
factors are presented in Table 3. In the multivariate analysis,
Figure 2. Progression-free survival rates after salvage ASCT according to the
duration of response after the ﬁrst ASCT (<40 or >40 months).
Table 2
Salvage ASCT
Variable Patients
(N ¼ 81)
Median age at the time of salvage ASCT (range) 58 (35-71)
Novel induction regimen before salvage ASCT
VAD 23 (29%)
Bortezomib-dexamethasone or lenalidomide-
dexamethasone or thalidomide-dexamethasone
26 (32%)
VTD or VRD 10 (12%)
Others 18 (22%)
None 4 (5%)
Conditioning regimen before salvage ASCT
Melphalan 220 mg/m2 12 (15%)
Melphalan 200 mg/m2 45 (56%)
Melphalan 140 mg/m2 9 (11%)
Melphalan þ busulphan 2 (2%)
Others 13 (16%)
Response after salvage ASCT
VGPR 54 (67%)
PR 21 (26%)
SD 5 (6%)
PD 1 (1%)
Transplantation-related death 0
Consolidation therapy after salvage ASCT
Bortezomib-dexamethasone 6 (7%)
VTD 2 (3%)
VRD 4 (5%)
Lenalidomide-dexamethasone 4 (5%)
None 65 (80%)
Maintenance therapy after salvage ASCT
Thalidomide 11 (14%)
Lenalidomide 12 (15%)
Bortezomib 3 (4%)
Other 4 (5%)
None 51 (63%)
VAD indicates vincristine, adriamycin, dexamethasone; VTD, bortezomib-
thalidomide-dexamethasone; VRD, bortezomib-lenalidomide-dexamethasone;
SD, stable disease; PD, progressive disease.
E. Lemieux et al. / Biol Blood Marrow Transplant 19 (2013) 445e449 447three independent factors unfavorably affected PFS: a short
duration of response to the ﬁrst ASCT, a response less than
a VGPR after salvage therapy, and no maintenance treatment
after salvage ASCT. Age over 60 years and a short duration of
response after the ﬁrst ASCT were the two factors adversely
affecting OS from the time of diagnosis and OS from the
time of salvage ASCT (Table 4).
DISCUSSION
Currently, there is no broadly accepted standard treat-
ment for patients with relapsed/refractory MM [21]. For theFigure 1. Progression-free and overall survival rates.selection of an appropriate treatment strategy at this stage,
both disease-related and patient-related factors and, impor-
tantly, the type of previous therapy need to be considered
[21-25]. Disease-related factors include the quality and
duration of response to previous therapies and the aggres-
siveness of the relapse, whereas patient-related factors
comprise pre-existing toxicities, comorbid conditions,
quality of life, age, and performance status [21-25]. Regarding
previous therapies, it is important to take into account if the
patient has been exposed to alkylators or to the novel agents,
immunomodulatory drugs and proteasome inhibitors, and if
this was alone or in combination, to deﬁne the best strategy
[21-26].
Intensive therapy can always be considered at this stage
[21]. Although allogeneic transplantation shows limited
clinical beneﬁt for the treatment of patients with relapsed/
refractory MM [27], available data suggest that a second
autologous transplantation may be beneﬁcial and well
tolerated for some patients in this setting [21-23]. The overall
response rates in studies range from 55% to 69%, with a 100-
day mortality rate <10% [8-19]. However, the small sample
size used in these studies complicates the identiﬁcation of
the ideal candidate for this treatment approach. Most reports
suggest that the duration of the ﬁrst response to ASCT is the
major prognostic factor [8-19].
In the current retrospective study, we conﬁrm that
salvage ASCT at the time of relapse is a valuable and feasible
option. Response rates were high, with more than 90% ofFigure 3. Progression-free survival rates after salvage ASCT according to
maintenance therapy.
Table 3
Univariate Analysis of Variables Unfavorably Affecting Progression-Free and Overall Survival Rates
Variable (P < .05) HR 95% CI P Value
Progression-free survival after salvage ASCT
Duration of response after ﬁrst ASCT < 24 mo 2.40 [1.21, 4.76] .01
Duration of response after ﬁrst ASCT < 40 mo 2.78 [1.62, 4.77] .0002
Response after salvage ASCT < VGPR 2.48 [1.42, 4.10] .001
No maintenance therapy after salvage ASCT 3.32 [1.76, 6.29] .0002
Overall survival from diagnosis
Age > 60 y 5.09 [2.33, 11.10] <.0001
b2-microglobulin at diagnosis > 3.5 mg/L 2.21 [1.12, 4.35] .02
Duration of response after ﬁrst ASCT < 24 mo 6.85 [3.27, 14.86] <.0001
Duration of response after ﬁrst ASCT < 40 mo 7.08 [3.35, 14.99] <.0001
Response after ﬁrst ASCT < VGPR 2.80 [1.48, 5.28] .00015
Response after salvage ASCT < VGPR 3.81 [2.00, 7.23] <.0001
No maintenance therapy after salvage ASCT 2.83 [1.23, 6.49] .01
Overall survival from salvage ASCT
Age > 60 y 2.89 [1.43, 5.86] .003
Duration of response after ﬁrst ASCT < 24 mo 3.65 [1.77, 7.53] .0004
Duration of response after ﬁrst ASCT < 40 mo 3.47 [1.68, 7.18] .0008
Response after ﬁrst ASCT < VGPR 2.25 [1.18-4.29] .01
Response after salvage ASCT < VGPR 2.76 [1.43, 5.31] .002
HR indicates hazard ratio; CI, conﬁdence interval.
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related mortality. Our results thereby conﬁrm those re-
ported by various groups [9-19]. In addition, similar to what
has previously been described, we show that the duration of
response to the ﬁrst ASCT is the major prognostic factor for
both PFS and OS. In our series, a duration of response of at
least 24 months to the ﬁrst intensive therapy was associated
with a longer PFS and OS. This cut-off value of 24months was
also described in a series of 81 patients treated at the Prin-
cess Margaret Hospital, Toronto, Ontario, Canada [16].
Different cut-off values, ranging from 12 to 24 months,
have already been proposed by several investigators
[9,15,19]. Interestingly, we found that a response of less than
VGPR after salvage ASCT was an independent adverse prog-
nostic factor for PFS. It is only the second time this factor,
which is a known prognostic factor in the frontline ASCT
setting [3], has been described to be important in the context
of salvage ASCT [16]. Of note, we were able to analyze the
impact of maintenance therapy after salvage ASCT and
showed for the ﬁrst time that maintenance might signiﬁ-
cantly prolong the duration of response. The role of main-
tenance in the frontline setting is a matter of controversy
[28], despite the overwhelming strong evidence of an
improvement in PFS when immunomodulatory drugs are
administered after upfront ASCT [29,30]. Our ﬁndings willTable 4
Multivariate Cox Regression Analysis of Variables Unfavorably Affecting Progressio
Variable (P < .05) HR
Progression-free survival
Duration of response after ﬁrst ASCT < 24 mo 2.25
Duration of response after ﬁrst ASCT < 40 mo 2.46
Response after salvage ASCT < VGPR 1.97
No maintenance therapy after salvage ASCT 3.40
Overall survival fro
Age > 60 y 4.00
Duration of response after ﬁrst ASCT < 24 mo 14.90
Duration of response after ﬁrst ASCT < 40 mo 4.67
Overall survival from
Age > 60 y 3.62
Duration of response after ﬁrst ASCT < 24 mo 8.25
Duration of response after ﬁrst ASCT < 40 mo 4.45
HR indicates hazard ratio; CI, conﬁdence interval.feed the debate on the role of maintenance in the setting of
salvage ASCT. Of note in our analysis is that some patients
received an autograft that had been cryopreserved and
stored for 10 years before the salvage ASCT [8].
There are a number of limitations to our study. First, it
was not an intent-to-treat analysis, and we lack precise data
on how many patients were excluded from salvage ASCT
because of comorbidity, an insufﬁcient amount of stem cells,
or progressive and/or refractory disease. This selection bias is
themost important shortcoming. Second, the study is related
to the long period of accrual, which explains the heteroge-
neity in the treatment received by the patients, both as part
of frontline therapy and at the time of relapse. Clearly, the
role of salvage ASCT has to be re-examined in the context of
novel agents. Moreover, we collected cytogenetic data in only
some patients, and salvage therapies have to be evaluated, if
possible, with this information available.
Nevertheless, our data show that salvage ASCT is
a feasible option that should be routinely considered at the
time of relapse for patients with a response duration of more
than 2 years to frontline high-dose therapy. The feasibility of
salvage ASCTmight also be improved in the futurewith novel
strategies of stem cell collection, such as the use of plerixafor,
which allows the collection of stem cells in patients previ-
ously exposed to high-dose therapy [31].n-Free and Overall Survival Rates
95% CI P Value
after salvage ASCT
[1.02, 4.98] .04
[1.40, 4.32] .001
[1.02, 3.80] .04
[1.72, 6.69] .0004
m diagnosis
[1.50, 10.71] .006
[3.98, 55.70] <.0001
[2.04, 10.70] .0003
salvage ASCT
[1.39, 9.42] .008
[2.93, 23.22] <.0001
[1.93, 10.24] .0004
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